On August 2, 2021, Nanjing Leadsbiolab Biotechnology Co., Ltd. (hereinafter referred to as "Leadsbiolab")has announced that its LBL-024 for PD-L1 / 4-1BB bispecific antibody injection was approved by the U.S. Food and Drug Administration (FDA) for Clinical trial license.
LBL-024 is a bispecific antibody independently researched and developed by leadsbiolab and wholly owned intellectual property rights. LBL-024 is a highly potential anti-tumor bispecific antibody, which consists of high affinity monoclonal antibody against PD-L1 and 4-1BB single chain antibody. LBL-024 can block PD-1 / PD-L1 immunosuppressive pathway and conditionally activate 4-1BB costimulatory receptor, thus playing a dual synergistic role of relieving immunosuppression (releasing the brake) and activating the immune system (stepping on the gas).
Source: Leadsbiolab website